Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat

Kenneth P. Meyers, Cristine L. Czachowski, John W. Coffey

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pretreatment of rats with the human interleukin-1 receptor antagonist (IL-1ra) by the subcutaneous route at -0.5 h, relative to the intrapleural injection of carrageenan (CG), suppressed the infiltration of cells into the pleural cavity of intact and adrenalectomized rats at 5 h (28 and 74% reduction in intact animals at 0.3 and 10 mg/kg, respectively). Exudate volume at 5 h was also suppressed at dosages of IL-1ra ≥ 3 mg/kg. IL-1ra was still effective as an antiinflammatory agent in the 5-h pleurisy model when administered 1 or 2 h, but not 3 h, after CG. The addition of IL-1ra to a maximally effective antiinflammatory dosage of indomethacin (5 mg/kg) resulted in further reductions of cell number and exudate volume, suggesting that the antiinflammatory effects of IL-1ra in the 5-h model were not due solely to inhibition of IL-1-induced prostaglandin biosynthesis. The antiinflammatory effects of suboptimal dosages of IL-1ra and dexamethasone, administered in combination, were essentially additive. In 24-h pleurisy, IL-1ra reduced exudate volume and PMN number after a single dosage of 10 mg/kg, subcutaneously at -0.5 h and after dosages of 3 mg/kg at -0.5 and 5 h. Additional dosages of IL-1ra (3 mg/kg) at 10 and 15 h did not further inhibit PMN accumulation. Treatment with IL-1ra did not affect macrophage accumulation in 24-h CG-induced pleurisy. IL-1ra was not active as an antiinflammatory agent in the 24-h pleurisy model after three dosages of IL-1ra (3mg/kg) at 5, 10 and 15 h.

Original languageEnglish (US)
Pages (from-to)121-134
Number of pages14
JournalInflammation
Volume17
Issue number2
DOIs
StatePublished - Apr 1993
Externally publishedYes

Fingerprint

Pleurisy
Interleukin-1 Receptors
Carrageenan
Anti-Inflammatory Agents
Exudates and Transudates
Therapeutics
Pleural Cavity
Interleukin-1
Indomethacin
Dexamethasone
Prostaglandins
Cell Count
Macrophages

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology
  • Cell Biology

Cite this

Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat. / Meyers, Kenneth P.; Czachowski, Cristine L.; Coffey, John W.

In: Inflammation, Vol. 17, No. 2, 04.1993, p. 121-134.

Research output: Contribution to journalArticle

Meyers, Kenneth P. ; Czachowski, Cristine L. ; Coffey, John W. / Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat. In: Inflammation. 1993 ; Vol. 17, No. 2. pp. 121-134.
@article{37c20b1c9bb94d5e8f9d181dfcb52afe,
title = "Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat",
abstract = "Pretreatment of rats with the human interleukin-1 receptor antagonist (IL-1ra) by the subcutaneous route at -0.5 h, relative to the intrapleural injection of carrageenan (CG), suppressed the infiltration of cells into the pleural cavity of intact and adrenalectomized rats at 5 h (28 and 74{\%} reduction in intact animals at 0.3 and 10 mg/kg, respectively). Exudate volume at 5 h was also suppressed at dosages of IL-1ra ≥ 3 mg/kg. IL-1ra was still effective as an antiinflammatory agent in the 5-h pleurisy model when administered 1 or 2 h, but not 3 h, after CG. The addition of IL-1ra to a maximally effective antiinflammatory dosage of indomethacin (5 mg/kg) resulted in further reductions of cell number and exudate volume, suggesting that the antiinflammatory effects of IL-1ra in the 5-h model were not due solely to inhibition of IL-1-induced prostaglandin biosynthesis. The antiinflammatory effects of suboptimal dosages of IL-1ra and dexamethasone, administered in combination, were essentially additive. In 24-h pleurisy, IL-1ra reduced exudate volume and PMN number after a single dosage of 10 mg/kg, subcutaneously at -0.5 h and after dosages of 3 mg/kg at -0.5 and 5 h. Additional dosages of IL-1ra (3 mg/kg) at 10 and 15 h did not further inhibit PMN accumulation. Treatment with IL-1ra did not affect macrophage accumulation in 24-h CG-induced pleurisy. IL-1ra was not active as an antiinflammatory agent in the 24-h pleurisy model after three dosages of IL-1ra (3mg/kg) at 5, 10 and 15 h.",
author = "Meyers, {Kenneth P.} and Czachowski, {Cristine L.} and Coffey, {John W.}",
year = "1993",
month = "4",
doi = "10.1007/BF00916099",
language = "English (US)",
volume = "17",
pages = "121--134",
journal = "Inflammation",
issn = "0360-3997",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat

AU - Meyers, Kenneth P.

AU - Czachowski, Cristine L.

AU - Coffey, John W.

PY - 1993/4

Y1 - 1993/4

N2 - Pretreatment of rats with the human interleukin-1 receptor antagonist (IL-1ra) by the subcutaneous route at -0.5 h, relative to the intrapleural injection of carrageenan (CG), suppressed the infiltration of cells into the pleural cavity of intact and adrenalectomized rats at 5 h (28 and 74% reduction in intact animals at 0.3 and 10 mg/kg, respectively). Exudate volume at 5 h was also suppressed at dosages of IL-1ra ≥ 3 mg/kg. IL-1ra was still effective as an antiinflammatory agent in the 5-h pleurisy model when administered 1 or 2 h, but not 3 h, after CG. The addition of IL-1ra to a maximally effective antiinflammatory dosage of indomethacin (5 mg/kg) resulted in further reductions of cell number and exudate volume, suggesting that the antiinflammatory effects of IL-1ra in the 5-h model were not due solely to inhibition of IL-1-induced prostaglandin biosynthesis. The antiinflammatory effects of suboptimal dosages of IL-1ra and dexamethasone, administered in combination, were essentially additive. In 24-h pleurisy, IL-1ra reduced exudate volume and PMN number after a single dosage of 10 mg/kg, subcutaneously at -0.5 h and after dosages of 3 mg/kg at -0.5 and 5 h. Additional dosages of IL-1ra (3 mg/kg) at 10 and 15 h did not further inhibit PMN accumulation. Treatment with IL-1ra did not affect macrophage accumulation in 24-h CG-induced pleurisy. IL-1ra was not active as an antiinflammatory agent in the 24-h pleurisy model after three dosages of IL-1ra (3mg/kg) at 5, 10 and 15 h.

AB - Pretreatment of rats with the human interleukin-1 receptor antagonist (IL-1ra) by the subcutaneous route at -0.5 h, relative to the intrapleural injection of carrageenan (CG), suppressed the infiltration of cells into the pleural cavity of intact and adrenalectomized rats at 5 h (28 and 74% reduction in intact animals at 0.3 and 10 mg/kg, respectively). Exudate volume at 5 h was also suppressed at dosages of IL-1ra ≥ 3 mg/kg. IL-1ra was still effective as an antiinflammatory agent in the 5-h pleurisy model when administered 1 or 2 h, but not 3 h, after CG. The addition of IL-1ra to a maximally effective antiinflammatory dosage of indomethacin (5 mg/kg) resulted in further reductions of cell number and exudate volume, suggesting that the antiinflammatory effects of IL-1ra in the 5-h model were not due solely to inhibition of IL-1-induced prostaglandin biosynthesis. The antiinflammatory effects of suboptimal dosages of IL-1ra and dexamethasone, administered in combination, were essentially additive. In 24-h pleurisy, IL-1ra reduced exudate volume and PMN number after a single dosage of 10 mg/kg, subcutaneously at -0.5 h and after dosages of 3 mg/kg at -0.5 and 5 h. Additional dosages of IL-1ra (3 mg/kg) at 10 and 15 h did not further inhibit PMN accumulation. Treatment with IL-1ra did not affect macrophage accumulation in 24-h CG-induced pleurisy. IL-1ra was not active as an antiinflammatory agent in the 24-h pleurisy model after three dosages of IL-1ra (3mg/kg) at 5, 10 and 15 h.

UR - http://www.scopus.com/inward/record.url?scp=0027465024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027465024&partnerID=8YFLogxK

U2 - 10.1007/BF00916099

DO - 10.1007/BF00916099

M3 - Article

VL - 17

SP - 121

EP - 134

JO - Inflammation

JF - Inflammation

SN - 0360-3997

IS - 2

ER -